{
    "clinical_study": {
        "@rank": "72062", 
        "acronym": "Kudzu MRS", 
        "arm_group": [
            {
                "arm_group_label": "Kudzu extract treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Kudzu (2 mg) will be administered as a pretreatment 2 \u00bd hours before a drinking session.\nDuring the medication week, participants will take 2 capsules three times a day for a total dose of 3 grams of kudzu."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be administered as a pretreatment 2 \u00bd hours before a drinking session.\nDuring the medication week, participants will take 2 capsules three times a day."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to test whether treatment with kudzu extract will increase the rate\n      at which alcohol enters the brain as measured by rapid proton magnetic resonance\n      spectroscopy (1H-MRS)."
        }, 
        "brief_title": "Kudzu Effects on Brain Ethanol Levels: Proton Spectroscopy Assessment", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Alcohol Consumption", 
            "Cerebral Blood Flow"
        ], 
        "condition_browse": {
            "mesh_term": "Alcohol Drinking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Capable of understanding and complying with the protocol\n\n          -  Good physical and mental health (normal physical exam, ECG, blood and urine\n             chemistries, no psychopathologies)\n\n          -  Body Mass Index between 18-30, inclusive\n\n          -  Age 21-40 years\n\n          -  Moderate alcohol drinkers (less than 20 drinks/week)\n\n          -  Have a stable living situation with current postal address\n\n          -  No contraindications to MR scanning (see MR scanning exclusion criteria below)\n\n        Exclusion Criteria:\n\n          -  Concurrent diagnosis of Axis I disorder\n\n          -  Current or past alcohol dependence; may meet criteria for alcohol abuse.  Other drug\n             dependence acceptable only if greater than 3 years.\n\n          -  Current drug abuse (other than alcohol or marijuana abuse).  Past drug abuse is\n             acceptable.\n\n          -  Subjects cannot be actively seeking treatment for any drug or alcohol dependence.\n\n          -  Subjects cannot use marijuana more than once a week. Marijuana abuse/dependence are\n             acceptable if the use criteria is met.\n\n          -  Maintained on an antipsychotic or antidepressant medication; taking prescription\n             medications except certain short-term anti fungal agents and some tropical creams for\n             dermal conditions.\n\n          -  Tobacco use greater than 10 cigarettes per day\n\n          -  History of major head trauma resulting in cognitive impairment or history of seizure\n             disorder\n\n          -  Heavy caffeine use (greater than 500 mg on a regular, daily basis)\n\n          -  For female volunteers, a positive pregnancy test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739842", 
            "org_study_id": "2012-P-001780", 
            "secondary_id": "AA10536"
        }, 
        "intervention": {
            "arm_group_label": "Kudzu extract treatment", 
            "intervention_name": "Kudzu extract", 
            "intervention_type": "Dietary Supplement", 
            "other_name": [
                "Kudzu root extract (NPI-031)", 
                "Puerariae lobata", 
                "Alkontrol-Herbal\u00ae"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alcohol consumption", 
            "Kudzu extract", 
            "Cerebral blood flow"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Kudzu Effects on Brain Ethanol Levels: Proton Spectroscopy Assessment", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the effects of kudzu extract treatment on the rate at which alcohol enters the brain and to determine if this is due to a change in cerebral blood flow as measured by rapid proton magnetic resonance spectroscopy (1H-MRS).", 
            "measure": "Rate at which alcohol enters the brain", 
            "safety_issue": "No", 
            "time_frame": "2.5 hours after drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739842"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mclean Hospital", 
            "investigator_full_name": "Scott Lukas", 
            "investigator_title": "Director, McLean Imaging Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Impact of alcohol and kudzu on resting state networks (RSN).", 
            "safety_issue": "No", 
            "time_frame": "2.5 hours after drug administration"
        }, 
        "source": "Mclean Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Mclean Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013", 
        "why_stopped": "Funding was not received for this study."
    }
}